论文信息 - Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.

Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.

The development of potent, orally bioavailable (in rat) and selective dihydroquinazolinone inhibitors of p38alpha MAP kinase is described. These analogues are hybrids of a pyridinylimidazole p38alpha inhibitor reported by Merck Research Laboratories and VX-745. Optimization of the C-5 phenyl and the C-7 piperidinyl substituents led to the identification of 15i which gave excellent suppression of TNF-alpha production in LPS-stimulated whole blood (IC(50)=10nM) and good oral exposure in rats (F=68%, AUCn PO=0.58 microM h).

[1] E. Goldsmith,et al. Structural basis of inhibitor selectivity in MAP kinases. , 1998, Structure.

[2] G. Bemis,et al. The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. , 1997, Chemistry & biology.

[3] J. Boehm,et al. New inhibitors of p38 kinase , 2000 .

[4] E. A. O'neill,et al. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. , 1999, Journal of Medicinal Chemistry.

[5] Paul R. Caron,et al. Crystal Structure of p38 Mitogen-activated Protein Kinase* , 1996, The Journal of Biological Chemistry.

[6] J. Bondeson,et al. TUMOUR NECROSIS FACTOR AS A THERAPEUTIC TARGET IN RHEUMATOID ARTHRITIS AND OTHER CHRONIC INFLAMMATORY DISEASES: THE CLINICAL EXPERIENCE WITH INFLIXIMAB (REMICADE™) , 2001, International journal of clinical practice.

[7] L. Tong,et al. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket , 1997, Nature Structural Biology.

[8] D. Witty. 27th National Medicinal Chemistry Symposium. , 2000, IDrugs : the investigational drugs journal.